Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05149898 · ClinicalTrials.gov registry record · Phase 2
Open-Label Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With 22q11.2 Deletion Syndrome (INSPIRE)
A Phase 2 study, sponsored by Harmony Biosciences Management.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT05149898 is a Phase 2 study that has completed, run by Harmony Biosciences Management. The registered enrollment target is 20 participants.
The verdict
NCT05149898, a Phase 2 study, has completed, sponsored by Harmony Biosciences Management.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
To evaluate the safety and tolerability of ZYN002 administered as a transdermal gel formulation, for up to 38 weeks, in participants ages 4 to \<18 years, in the treatment of 22q.11.2 Deletion syndrome (22qDS).
Interventions
- DRUG ZYN002
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2020-02-19 |
| Est. Completion | 2022-11-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05149898
The ClinicalTrials.gov registry entry for NCT05149898 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Harmony Biosciences Management, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ZYN002 is the first listed.
NCT05149898 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05149898 about?
NCT05149898 is a clinical study titled "Open-Label Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With 22q11.2 Deletion Syndrome (INSPIRE)". To evaluate the safety and tolerability of ZYN002 administered as a transdermal gel formulation, for up to 38 weeks, in participants ages 4 to \<18 years, in the treatment of 22q.11.2 Deletion syndrome (22qDS).
What is the current status of trial NCT05149898?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2020-02-19. Estimated completion is 2022-11-09.
What interventions are being tested in trial NCT05149898?
The interventions under investigation include: ZYN002 (DRUG).
Who is sponsoring clinical trial NCT05149898?
This trial is sponsored by Harmony Biosciences Management, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.